Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track SCYX with free AI briefings, catalyst countdowns, and dilution alerts.

SCYX · SCYNEXIS INC

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$47.2M Cash on Hand
12.7mo Cash Runway
Follow SCYX by email Get an email when SCYX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about SCYX, unsubscribe in one click. Privacy

📣 What SCYX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Caspofungin Candidiasis, Invasive Phase 3 · NCT05178862 Terminated
Ibrexafungerp (SCY-078) Invasive Candidiasis Phase 3 · NCT03059992 Completed
Ribavirin Hepatitis C Infection Phase 2 · NCT01265511 Completed
SCY-635 Hepatitis C Infection Phase 2 · NCT01265511 Completed
[14C]-Ibrexafungerp Fungal Infection Phase 1 · NCT04307082 Completed
4-Dimethylaminoazobenzene Pharmacokinetics Phase 1 · NCT04092725 Completed
Progesterone Receptor Isoform A Pharmacokinetics Phase 1 · NCT04092751 Completed

Also used in these trials (approved or third-party drugs, not SCYX's own candidates): Fluconazole, Micafungin, Peginterferon Alfa-2A, Voriconazole.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

SCYX holds $47.2M in cash and short-term investments (as of Sep 30, 2026) and burns about $11.2M/quarter from operations, an estimated runway of 12.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 28 · Moderate

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SCYX files for a raise →

👥 Who Owns SCYX

Insiders 24.8% Other 5%+ holders 75.2% Institutions (46 holders) 0% Public and other holders 0%
HolderTypeShares% of sharesAs of
Squadron Master Fund LP 5%+ holder (13G) 7,608,695 76.45% 2026-03-31
Great Point Partners, LLC Institution (13G, 5%+) 4,076,068 40.95% 2026-06-30
Gonzalez David Angulo
Chief Executive Officer, Director · +934,116 options
Insider 1,357,126 13.64% 2026-04-01
Adage Capital Management, L.P. Institution (13G, 5%+) 1,041,824 10.47% 2026-06-30
CVI Investments, Inc. 5%+ holder (13G) 615,522 6.18% 2026-06-30
Scott Sukenick
Chief Legal Officer · +354,282 options
Insider 574,539 5.77% 2026-01-29
ivor Macleod
Chief Financial Officer · +354,282 options
Insider 398,529 4.00% 2026-01-29
Steven C Gilman
Director · +46,000 options
Insider 70,000 0.70% 2025-06-26
Guy Macdonald
Director · +48,875 options
Insider 12,625 0.13% 2026-06-26
Brian Philippe Tinmouth
Director · +48,875 options
Insider 12,125 0.12% 2026-06-26
Armando Anido
Director · +48,875 options
Insider 11,750 0.12% 2026-06-26
Ann Hanham
Director · +48,875 options
Insider 11,577 0.12% 2026-06-26

Share count 9,953,155 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full SCYX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SCYX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.